



Our position on the 2030 agenda for sustainable development



THE GLOBAL GOALS
For Sustainable Development

In September 2015, world leaders adopted the 2030 Agenda for Sustainable Development. The 2030 Agenda comprises of 17 universal Sustainable Development Goals (SDGs), or Global Goals, which will guide policy and funding for the next 15 years, beginning with a historic pledge to end poverty.

The Novo Nordisk position

Novo Nordisk welcomes and supports the 17 universal Global Goals, and 169 targets, and believes that an integrated approach implemented through partnerships and involving the private sector, across the multiple goals is crucial to achieving them. We particularly welcome the recognition of the importance of the growing burden of diabetes and other non-communicable diseases (NCDs).

Novo Nordisk's view is that the targets are interlinked and that health is a prerequisite for sustainable development. From a human and economic perspective, efforts to enhance health for all have potential to yield high returns on investment for all. Consequently, the company will systematically review its contribution to each of the 17 Global Goals and as a healthcare company we will put special emphasis on health and improving the wellbeing and life of patients.

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.



ESTABLISHED IN
DENMARK IN
1923



AFFILIATES IN
75
COUNTRIES



PRODUCTS
MARKETED IN
180+
COUNTRIES



MORE THAN
41,000
EMPLOYEES

Contributing with our knowledge and expertise and working through partnerships, we can have an impact on several goals and targets.



GOAL 3

ENSURE HEALTHY LIVES AND PROMOTE WELL-BEING FOR ALL AT ALL AGES

TARGET 3.2 By 2030, end preventable deaths of newborns and children under 5 years of age, with all countries aiming to reduce neonatal mortality to at least as low as 12 per 1,000 live births and under-5 mortality to at least as low as 25 per 1,000 live births
Novo Nordisk believes in taking a life-course and person-centred approach to non-communicable diseases worldwide. Particularly in low- and middle-income countries, our goal is to contribute to the development of healthcare systems, which can address the triple-burden of disease relating to maternal and child health, communicable diseases and NCDs.

TARGET 3.4 By 2030, reduce by one-third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being

Novo Nordisk believes that achieving this target will require a balanced strategy ranging from effective prevention of diabetes and other NCDs to effective early detection policies and appropriate care.

TARGET 3.8 Achieve universal health coverage, including financial risk protection, access to quality essential healthcare services and access to safe, effective, quality and affordable essential medicines and vaccines for all

Novo Nordisk advocates for equal rights and accessibility to healthcare for all as stated in the United Nations Universal Declaration of Human Rights.



GOAL 11

MAKE CITIES AND HUMAN SETTLEMENTS INCLUSIVE, SAFE, RESILIENT AND SUSTAINABLE

TARGET 11.3 By 2030, enhance inclusive and sustainable urbanisation and capacity for participatory, integrated and sustainable human settlement planning and management in all countries

Novo Nordisk believes that cities are important focal points for tackling diabetes as 65% of all people with diabetes live in cities, amounting to 270 million people.¹ By 2040, this proportion is projected to rise to 74%, corresponding to almost 480 million people.¹ Novo Nordisk aims to contribute with expertise and insights to ensure that diabetes and other NCD's on the rise in cities are high on the urbanisation agenda and are addressed by those managing and designing cities.



GOAL 13

TAKE URGENT ACTION TO COMBAT CLIMATE CHANGE AND ITS IMPACTS

TARGET 13.2 Integrate climate change measures into national policies, strategies and planning

At Novo Nordisk we are committed to conducting our business in a financially, environmentally and socially responsible way. Climate change has global implications on all three dimensions, and poses a significant threat to human health and development. Therefore taking steps to reduce our impact is both an act of long-term risk mitigation and corporate responsibility.



GOAL 16

PROMOTE PEACEFUL AND INCLUSIVE SOCIETIES FOR SUSTAINABLE DEVELOPMENT, PROVIDE ACCESS TO JUSTICE FOR ALL AND BUILD EFFECTIVE, ACCOUNTABLE AND INCLUSIVE INSTITUTIONS AT ALL LEVELS

TARGET 16.5 Substantially reduce corruption and bribery in all their forms

Novo Nordisk never compromises on business ethics. This is set out in the Novo Nordisk Way², a set of guiding principles which underpin every decision we make. We conduct all activities in an ethical, open and honest manner.

TARGET 16.6 Develop effective, accountable and transparent institutions at all levels

Novo Nordisk believes it is important to create a level playing field for responsible business and contributes in multiple ways in industry and cross sector fora.



GOAL 17

STRENGTHEN THE MEANS OF IMPLEMENTATION AND REVITALIZE THE GLOBAL PARTNERSHIP FOR SUSTAINABLE DEVELOPMENT

TARGET 17.7 Encourage and promote effective public, public-private and civil society partnerships, building on the experience and resourcing strategies of partnerships

Novo Nordisk works to encourage and promote effective public-private partnerships as a means of creating value for all stakeholders. We work in partnership with governments, international organisations, patients and their organisations, civil society, healthcare providers, academia and industry bodies to improve prevention, early detection and standards of care for people with diabetes and other NCDs. Many of these partnership activities fall under our Changing Diabetes[®] platform or promote sustainable business more broadly.

TARGET 17.19 By 2030, build on existing initiatives to develop measurements of progress on sustainable development that complement gross domestic product, and support statistical capacity-building in developing countries

Novo Nordisk believes that the establishment of a formal framework to register, monitor and report on the commitments and actions of all actors, including the private sector, to address the SDGs is needed.

Visit www.novonordisk.com to learn more about our position on the 2030 Agenda for Sustainable Development and our ongoing contributions to achieve the targets.

1. IDF. International Diabetes Federation. IDF Diabetes Atlas. 7th edn. Brussels, Belgium: International Diabetes Federation, 2015

2. Novo Nordisk. The Novo Nordisk WAY. Available at: <http://www.novonordisk.com/about-novonordisk/novo-nordisk-way.html>